As always, it was a pleasure to meet our Expert Faculty Member, Dr Tobias Boettler (University of Freiburg, Freiburg, Germany) following the EASL ILC 2021 conference. This time we discuss his highlights from the recent meeting in the field of hepatitis.
Questions
- Could you give us an overview of what we learned about the antiviral drug VIR-2218 and its promise in the treatment of patients with hepatitis B at the meeting? (0:16)
- Results from the MYR301 phase 3 study were also presented. What do you feel they have taught us about the clinical utility of bulevirtide in the treatment of patients with chronic hepatitis D? (1:23)
- COVID-19 was clearly one of the key topics this year. What did we learn about the impact of the pandemic on efforts to eliminate Hepatitis C? (2:56)
- Could you summarise your highlights from the various viral hepatitis sessions presented at the conference? (4:33)
Disclosures: Dr Tobias Boettler has served as a consultant for Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June
